Table 2. Adverse Events during DTX.

	Overall	DTX	DTX+ADT	p value
CTCAE grade ≤2, n (%)
Thrombocytopenia	1 (2.1)	1 (4.8)	0 (0.0)	0.266
Anemia	8 (17.0)	3 (14.3)	5 (19.2)	0.657
Aspartate/alanine aminotransferase increased	14 (29.8)	5 (23.8)	9 (34.6)	0.426
Nausea & vomiting	29 (61.7)	15 (71.4)	14 (53.8)	0.223
Diarrhea	9 (19.1)	6 (28.6)	3 (11.5)	0.144
Constipation	13 (27.7)	8 (38.1)	5 (19.2)	0.155
Peripheral neuropathy	7 (14.9)	3 (14.3)	4 (15.4)	0.917
Dry mouth	14 (29.8)	8 (38.1)	6 (23.1)	0.268
Dry eye	12 (25.5)	7 (33.3)	5 (19.2)	0.275
Edema limbs	6 (12.8)	2 (9.5)	4 (15.4)	0.554
Myalgia	11 (23.4)	6 (28.6)	5 (19.2)	0.457
CTCAE grade ≥3, n (%)
Febrile neutropenia	8 (17.0)	4 (19.0)	4 (15.4)	0.742
Anemia	1 (2.1)	0 (0.0)	1 (3.8)	0.369
Nausea & vomiting	2 (4.3)	2 (9.5)	0 (0.0)	0.112
Peripheral neuropathy	2 (4.3)	0 (0.0)	2 (7.7)	0.199
Fatigue	2 (4.3)	1 (4.8)	1 (3.8)	0.878

CTCAE, common terminology criteria for adverse events; DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy.